REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

GLP-1 Fat Burner

Fat Lossintermediate
36
Peptides

3

Avg Daily mcg

2,479

Level

intermediate

Added

May 16, 2026

Overview

The GLP-1 Fat Burner is an intermediate-level fat loss stack that combines appetite regulation, mitochondrial activation, and targeted lipolysis into a comprehensive metabolic optimization protocol. This three-peptide approach attacks stubborn body fat from multiple angles while supporting energy levels and metabolic health markers throughout the cut. Semaglutide at 250mcg weekly is a GLP-1 receptor agonist that fundamentally resets appetite signaling. By mimicking the incretin hormone GLP-1, it acts on hypothalamic satiety centers to reduce hunger and food reward behavior, while simultaneously slowing gastric emptying and improving insulin sensitivity. At this moderate dose, users experience meaningful appetite suppression without the more intense gastrointestinal effects seen at higher doses. Clinical trials have demonstrated that GLP-1 agonists produce significant and sustained weight loss, with particular efficacy against visceral fat deposits. MOTS-c at 5000mcg three times weekly is a mitochondrial-derived peptide that activates AMPK (AMP-activated protein kinase)—the master metabolic switch that promotes fatty acid oxidation and glucose uptake into skeletal muscle. MOTS-c essentially tells your cells to burn more fuel, improving metabolic flexibility and exercise capacity. Research has shown it mimics some benefits of exercise at the cellular level, making it particularly valuable during caloric restriction when energy and training performance might otherwise decline. AOD-9604 at 300mcg daily is a modified fragment of human growth hormone that directly stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat creation) by activating beta-3 adrenergic receptors in adipose tissue. It accelerates fat mobilization without affecting blood glucose, appetite, or lean tissue—making it a precision tool for body composition. Protocol Notes: Semaglutide should be titrated gradually starting at lower doses over 3-4 weeks. MOTS-c is best administered on training days or in the morning. AOD-9604 should be injected subcutaneously in the morning on an empty stomach for optimal absorption. This stack is ideal for individuals with moderate peptide experience who want effective fat loss while maintaining energy and performance. It pairs well with a moderate caloric deficit and regular exercise. Typical cycles run 12-16 weeks with periodic metabolic bloodwork recommended.

Dosing Protocol

Semaglutide

Once per week

250 mcg

per dose

MOTS-c

3 times per week

5,000 mcg

per dose

AOD-9604

Every day

300 mcg

per dose

Goals & Evidence

Evidence tier:community

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.